Journal article
Factor XI inhibitors: what should clinicians know
Abstract
PURPOSE OF REVIEW: Factor XI (FXI) inhibitors were developed to address unmet needs and limitations of current anticoagulants and are currently being studied in several indications. In this paper, we review the rationale for the development of these agents and summarize what clinicians should know about drugs that target FXI.
RECENT FINDINGS: Patients with FXI deficiency may have a lower risk of venous thromboembolism and cardiovascular events …
Authors
Pandey A; Verma R; Eikelboom J; Verma S
Journal
Current Opinion in Cardiology, Vol. 38, No. 2, pp. 88–93
Publisher
Wolters Kluwer
Publication Date
March 2023
DOI
10.1097/hco.0000000000001015
ISSN
0268-4705